| Literature DB >> 27274838 |
Ayse Serra Artan1, Fatih Kircelli2, Ercan Ok3, Murvet Yilmaz4, Gulay Asci3, Cengiz Dogan5, Ozgur Oto1, Kutay Gunestepe2, Ali Basci3, Mehmet Sukru Sever1.
Abstract
BACKGROUND: Application and consequences of hemodialysis treatment may differ between genders; focusing on these differences may be useful to optimize outcomes.Entities:
Keywords: end-stage renal disease; gender; hemodialysis treatment
Year: 2016 PMID: 27274838 PMCID: PMC4886909 DOI: 10.1093/ckj/sfw013
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Demographic characteristics, features of hemodialysis practice and laboratory parameters in incident and prevalent male and female patientsa
| Parameter | Incident patients | Prevalent patients | ||||
|---|---|---|---|---|---|---|
| Female | Male | P | Female | Male | P | |
| Age (years) | 61.8 ± 14.9 | 60.2 ± 14.8 | 0.001 | 58.3 ± 15.2 | 56.5 ± 14.9 | <0.001 |
| BMI (kg/m2) | 26.8 ± 6.2 | 24.7 ± 4.5 | <0.001 | 25.8 ± 5.6 | 24.6 ± 4.4 | <0.001 |
| Dialysis vintage (months) | 0.5 ± 0.9 | 0.6 ± 0.9 | 0.6 | 62.7 ± 54.6 | 61.6 ± 54.0 | 0.3 |
| DM (%) | 39.8 | 34.6 | 0.003 | 28.5 | 27.2 | 0.2 |
| AVF (%)b | 48.8 ± 44.3 | 57.5 ± 43.3 | <0.001 | 77.2 ± 37.9 | 85.4 ± 31.1 | <0.001 |
| AVG (%)b | 1.7 ± 12.0 | 1.3 ± 10.1 | 0.08 | 3.9 ± 17.9 | 2.0 ± 13.1 | <0.001 |
| Untunneled catheter (%)b | 19.3 ± 34.7 | 19.1 ± 34.4 | 0.9 | 2.0 ± 11.4 | 1.5 ± 10.4 | 0.001 |
| Tunneled catheter (%)b | 27.7 ± 41.2 | 19.2 ± 35.8 | <0.001 | 12.1 ± 29.9 | 6.4 ± 22.3 | <0.001 |
| Blood flow (mL/min) | 296.3 ± 45.8 | 306.4 ± 45.6 | <0.001 | 319.5 ± 43.3 | 332.0 ± 41.2 | <0.001 |
| 1.4 ± 0.3 | 1.2 ± 0.2 | <0.001 | 1.6 ± 0.3 | 1.4 ± 0.2 | <0.001 | |
| Creatinine (mg/dL) | 5.83 ± 1.86 | 6.75 ± 2.31 | <0.001 | 7.13 ± 1.68 | 8.51 ± 2.25 | <0.001 |
| Potassium (mmol/L) | 4.77 ± 0.74 | 4.75 ± 0.72 | 0.1 | 5.06 ± 0.62 | 5.08 ± 0.62 | 0.4 |
| Albumin (g/dL) | 3.68 ± 0.47 | 3.72 ± 0.49 | 0.01 | 3.91 ± 0.32 | 3.98 ± 0.34 | <0.001 |
| Calcium (mg/dL) | 8.65 ± 0.70 | 8.61 ± 0.61 | 0.02 | 8.95 ± 0.65 | 8.93 ± 0.64 | 0.1 |
| Phosphorus (mg/dL)n | 4.56 ± 1.20 | 4.61 ± 1.21 | 0.5 | 4.74 ± 1.10 | 4.91 ± 1.20 | <0.001 |
| PTH (pg/mL) | 303.4 ± 247.9 | 281.5 ± 219.8 | 0.03 | 401.5 ± 370.3 | 429.5 ± 388.8 | 0.02 |
| Hemoglobin (g/dL) | 10.35 ± 1.26 | 10.71 ± 1.32 | <0.001 | 11.19 ± 1.13 | 11.68 ± 1.26 | <0.001 |
| Ferritin (ng/mL) | 688.3 ± 520.2 | 597.4 ± 440.2 | <0.001 | 905.8 ± 549.1 | 728.14 ± 527.1 | <0.001 |
BMI, body mass index; DM, diabetes mellitus; AVF, arteriovenous fistula; AVG, arteriovenous graft; PTH, parathyroid hormone.
aAll laboratory parameters were assessed in predialysis serum samples.
bPercentage of dialysis sessions performed by this particular access.
Three-year survival rates with regard to several parameters in the incident male and female patients
| P* | <Reference | Reference | >Reference | P** | |
|---|---|---|---|---|---|
| BMI | <21 kg/m2 ( | 21–25 kg/m2 ( | >25 kg/m2 ( | ||
| Female | 0.087 | 56.9% (243) | 75.0% (320) | 75.8% (735) | 0.009 |
| Male | 0.001 | 53.1% (324) | 66.1% (689) | 73.5% (726) | 0.002 |
| IDWG/dry weight | <1.4% | 1.4–4.2% | >4.2% | ||
| Female | <0.001 | 46.8% (188) | 75.8% (1012) | 65.3% (144) | 0.168 |
| Male | <0.001 | 38.9% (259) | 69.6% (1332) | 67.8% (213) | 0.646 |
| Predialysis systolic BP | <100 mmHg | 120–140 mmHg | >200 mmHg | ||
| Female | <0.001 | 29.5% (39) | 72.2% (761) | ***(1) | *** |
| Male | <0.001 | 22.0% (35) | 71.5% (1032) | ***(0) | *** |
| <1.2 | 1.2–1.4 | >1.4 | |||
| Female | <0.001 | 39.2% (166) | 70.9% (409) | 76.1% (672) | 0.028 |
| Male | <0.001 | 49.9% (475) | 68.9% (922) | 74.9% (279) | 0.609 |
| Hb | <9 g/dL | 11–12 g/dL | >13 g/dL | ||
| Female | *** | ***(173) | 84.9% (394) | ***(14) | *** |
| Male | <0.001 | 29.8% (191) | 78.9% (602) | 57.3% (55) | 0.109 |
| Phosphorus | <3.5 mg/dL | 3.5–5.5 mg/dL | >5.5 mg/dL | ||
| Female | <0.001 | 44.1% (196) | 75.8% (865) | 65.5% (209) | 0.188 |
| Male | <0.001 | 48.5% (247) | 64.6% (1134) | 83.3% (337) | 0.009 |
| PTH | <130 pg/mL | 130–585 pg/mL | >585 pg/mL | ||
| Female | <0.001 | 59.3% (247) | 77.3% (798) | 47.6% (110) | 0.024 |
| Male | <0.001 | 59.8% (363) | 69.3% (1070) | 68.1% (106) | 0.943 |
| Albumin | <3.5 g/dL | 3.5–4 g/dL | >4 g/dL | ||
| Female | <0.001 | 16.9% (294) | 75.4% (722) | 83.3% (253) | 0.027 |
| Male | <0.001 | 37.0% (398) | 66.9% (868) | 81.6% (454) | 0.001 |
BMI, body mass index; BP, blood pressure; Hb, hemoglobin; PTH, parathyroid hormone, IDWG, interdialytic weight gain.
P*: statistics for comparing lower values than the reference.
P**: statistics for comparing higher values than the reference.
***: statistics unavailable because of insufficient number of patients or a follow-up <3 years.
Fig. 1.Three-year survival rates in incident (A) and prevalent (B) female and male chronic hemodialysis patients.
Multivariate analysis of mortality in the incident (A) and prevalent (B) female and male chronic hemodialysis patients
| P | HR | 95.0% CI for HR | ||
|---|---|---|---|---|
| (A) | ||||
| Age | <0.001 | 1.028 | 1.018 | 1.037 |
| Gender (female) | 0.784 | 1.037 | 0.802 | 1.340 |
| Dialysis vintage | 0.425 | 1.051 | 0.931 | 1.186 |
| BMI | <0.001 | 0.943 | 0.920 | 0.967 |
| DM | 0.852 | 0.979 | 0.781 | 1.227 |
| Vascular access (AVF) | <0.001 | |||
| AVG | 0.105 | 1.970 | 0.869 | 4.471 |
| Untunneled catheter | <0.001 | 3.132 | 2.200 | 4.459 |
| Tunneled catheter | <0.001 | 1.854 | 1.422 | 2.418 |
| Various vascular access | 0.884 | 1.051 | 0.543 | 2.035 |
| e | <0.001 | 0.210 | 0.120 | 0.368 |
| Blood pump rate | 0.034 | 0.988 | 0.977 | 0.999 |
| Processed blood volume | 0.172 | 1.032 | 0.987 | 1.079 |
| IDWG/dry weight | 0.067 | 0.000 | 0.000 | 1.887 |
| Hemoglobin | <0.001 | 0.743 | 0.673 | 0.820 |
| Albumin | <0.001 | 0.413 | 0.312 | 0.547 |
| Total calcium | 0.007 | 1.343 | 1.084 | 1.665 |
| Phosphorus | 0.950 | 1.004 | 0.895 | 1.126 |
| iPTH | 0.778 | 1.000 | 1.000 | 1.001 |
| (B) | ||||
| Age | <0.001 | 1.037 | 1.030 | 1.043 |
| Gender (female) | 0.049 | 1.199 | 1.001 | 1.437 |
| Dialysis vintage | 0.196 | 1.001 | 0.999 | 1.003 |
| BMI | <0.001 | 0.928 | 0.911 | 0.945 |
| DM | <0.001 | 1.863 | 1.615 | 2.149 |
| Vascular access (AVF) | 0.001 | |||
| AVG | 0.882 | 0.970 | 0.654 | 1.441 |
| Untunneled catheter | <0.001 | 2.756 | 1.583 | 4.796 |
| Tunneled catheter | 0.005 | 1.329 | 1.091 | 1.618 |
| Various vascular access | 0.916 | 0.973 | 0.580 | 1.632 |
| | <0.001 | 0.219 | 0.141 | 0.339 |
| Blood pump rate | 0.667 | 1.002 | 0.994 | 1.009 |
| Processed blood volume | 0.235 | 0.982 | 0.954 | 1.012 |
| IDWG/dry weight | 0.065 | 1.072 | 0.996 | 1.153 |
| Hemoglobin | <0.001 | 0.820 | 0.767 | 0.878 |
| Albumin | <0.001 | 0.266 | 0.211 | 0.336 |
| Total calcium | <0.001 | 1.559 | 1.369 | 1.776 |
| Phosphorus | 0.057 | 0.925 | 0.854 | 1.002 |
| iPTH | 0.908 | 1.000 | 1.000 | 1.000 |
BMI, body mass index; AVF, arteriovenous fistula; AVG, arteriovenous graft; IDWG, interdiaytic weight gain; DM, diabetes mellitus; iPTH, intact parathyroid hormone; HR, hazard ratio; CI, confidence interval.
Three-year survival rates with regard to several parameters in the prevalent male and female patients
| P* | <Reference | Reference | >Reference | P** | |
|---|---|---|---|---|---|
| BMI | P* | <21 kg/m2 ( | 21–25 kg/m2 ( | >25 kg/m2 ( | P** |
| Female | 0.210 | 71.9% (643) | 74.4% (895) | 79.3% (1673) | 0.03 |
| Male | <0.001 | 68.3% (814) | 76.8% (1625) | 81.2% (1729) | 0.003 |
| IDWG/dry weight | <1.7% | 1.7–5.1% | >5.1% | ||
| Female | 0.003 | 69.6% (304) | 76.9% (2637) | 82.0% (260) | 0.1 |
| Male | <0.001 | 61.6% (302) | 77.2% (3433) | 84.8% (374) | 0.09 |
| Predialysis systolic BP | <100 mmHg | 120–140 mmHg | >200 mmHg | ||
| Female | 0.755 | 79.5% (243) | 77.4% (1560) | *** (2) | *** |
| Male | 0.036 | 74.2% (139) | 78.6% (2281) | *** (6) | *** |
| <1.2 | 1.2–1.4 | >1.4 | |||
| Female | <0.001 | 45.2% (108) | 68.9% (665) | 79.7% (2109) | <0.001 |
| Male | <0.001 | 59.3% (460) | 77.6% (2033) | 79.8% (1146) | 0.6 |
| Hb | <9 g/dL | 11–12 g/dL | >13 g/dL | ||
| Female | <0.001 | 61.4% (100) | 80.6% (1332) | 67.6% (132) | 0.02 |
| Male | <0.001 | 32.2% (87) | 79.0% (1515) | 86.1% (494) | 0.002 |
| Phosphorus | <3.5 mg/dL | 3.5-5.5 mg/dL | >5.5 mg/dL | ||
| Female | <0.001 | 55.9% (292) | 77.2% (2047) | 83.1% (n: 625) | 0.09 |
| Male | <0.001 | 53.5% (336) | 77.5% (2377) | 81.6% (1034) | 0.02 |
| PTH | <130 pg/mL | 130–585 pg/mL | >585 pg/mL | ||
| Female | <0.001 | 62.0% (355) | 78.7% (1851) | 81.7% (445) | 0.3 |
| Male | <0.001 | 61.9% (393) | 78.4% (2301) | 83.8% (643) | 0.01 |
| Albumin | <3.5 g/dL | 3.5–4 g/dL | >4 g/dL | ||
| Female | <0.001 | 35.4% (193) | 75.6% (1769) | 84.3% (989) | <0.001 |
| Male | <0.001 | 25.1% (239) | 73.1% (1764) | 86.1% (1747) | <0.001 |
BMI, body mass index; BP, blood pressure; Hb, hemoglobin; PTH, parathyroid hormone; IDWG, interdiaytic weight gain.
P*: statistics for comparing lower values than the reference.
P**: statistics for comparing higher values than the reference.
***: statistics unavailable because of insufficient number of patients or a follow-up <3 years.